COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA  (CABP) TREATMENT DRUGS MARKET ANALYSIS

Community-acquired Bacterial Pneumonia  (CABP) Treatment Drugs MarketSize and Trends

The global community-acquired bacterial pneumonia (CABP) treatment drugs market is estimated to be valued at US$ 1,269.73 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).

Figure 1. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Value (US$ Mn), by Region, 2020

The increasing prevalence of community-acquired pneumonia is expected to propel growth of the global community-acquired bacterial pneumonia (CABP) treatment drugs market

High prevalence of community-acquired pneumonia is expected to propel demand for community-acquired bacterial pneumonia (CABP) treatment drugs, which is expected to drive the market growth over the forecast period. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that the incidence of all?cause CAP each year was estimated at 0.81 per 1,000 individuals , rising to 6.95 per 1,000 person year in those aged 75 or older in Central Vietnam.

Moreover, increasing incidence of CAP were dominated by the effect of HIV. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that in 2017, the incidence of CAP were dominated by HIV if untreated, which was associated with a 17? to 35?fold increase in pneumococcal pneumonia in Sub-Saharan Africa region.

Figure 2. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Share (%), by Drug Class, 2020

Increasing incidence of CAP in North America is expected to boost the market growth

North America is expected to hold dominant position in the global community-acquired bacterial pneumonia (CABP) treatment drugs market, owing to rising incidence of community-acquired pneumonia in the region especially in the U.S. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that in the U.S. overall incidence of community-acquired pneumonia in adults was around 2.5 per 1000 person, rising to 6.3 and 16.4 per 1000 person in adults aged 65-79 and 80 years or older in 2017. Furthermore, according to the Centers for Disease Control and Prevention (CDC), an article published in 2018 states that, around 6 million cases  of community-acquired pneumonia were reported annually, resulting in an estimated 4.2 million ambulatory care visits, with adults age 65 and older most vulnerable to CAP.